
Please try another search
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidates are APR-1051, an orally bioavailable small-molecule inhibitor of WEE1 kinase that is in Phase 1 clinical trial for the treatment of patients with advanced solid tumors with biomarkers; and ATRN-119, an ATR inhibitor, which is in Phase 1/2a clinical trial for solid tumor indications. The company is headquartered in Doylestown, Pennsylvania.
Name | Age | Since | Title |
---|---|---|---|
Johan Christenson | 63 | 2016 | Independent Director |
Eric J. Brown | - | - | Member of Scientific Advisory Board |
Rifat Pamukcu | 67 | 2016 | Independent Director |
Zvi Gregorio Fridlender | - | - | Scientific & Clinical Advisory Board Member |
Bernd Robert Seizinger | 69 | 2015 | Independent Director |
Oren Gilad | 57 | 2011 | Co-Founder, CEO, President & Director |
Geoffrey I. Shapiro | - | 2019 | Scientific & Clinical Advisory Board Member |
Michael J. Grissinger | 72 | 2022 | Independent Director |
Gabriela Gruia | 68 | 2023 | Independent Director |
Timothy A. Yap | 50 | - | Scientific & Clinical Advisory Board Member |
Marc Duey | 68 | 2022 | Independent Director |
Karen E. Knudsen | - | - | Scientific & Clinical Advisory Board |
John B. Henneman | 63 | 2019 | Independent Director |
Richard Peters | 63 | 2020 | Independent Chairperson of the Board |
Jean-Pierre Bizzari | 71 | 2023 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review